Infertility as a risk factor of ovarian and breast cancer

References

• Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control11, 319–344 (2000).
   PubMedGoogle Scholar
• Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am. J. Epidemiol.140, 585–597 (1994).
   PubMedGoogle Scholar
• Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case–control study. Br. J. Cancer60, 592–598 (1989).
   PubMed Web of Science ®Google Scholar
• Oral E, Ilvan S, Tustas E et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur. J. Obstet. Gynecol. Reprod. Biol.109, 97–101 (2003).
   PubMed Web of Science ®Google Scholar
• Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N. Engl. J. Med.331, 771–776 (1994).
   PubMed Web of Science ®Google Scholar
• Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet. Gynecol.61, 403–407 (1983).
   PubMed Web of Science ®Google Scholar
• Meirow D, Schenker JG. The link between female infertility and cancer: epidemiology and possible aetiologies. Hum. Reprod. Update2, 63–75 (2003).
   Google Scholar
• Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil. Steril.94(5), 1787–1792 (2009).
   PubMedGoogle Scholar
• Brinton LA, Melton LJ III, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am. J. Epidemiol.129, 712–722 (1989).
   PubMed Web of Science ®Google Scholar
• Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of infertility drugs with in vitro fertilization. Lancet354, 1586–1590 (1999).
   PubMed Web of Science ®Google Scholar
• Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am. J. Epidemiol.168(1), 49–57 (2008).
   PubMedGoogle Scholar
• Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann. Intern. Med.130, 270–277 (1999).
   PubMed Web of Science ®Google Scholar
• Berrino F, Muti P, Micheli A et al. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl Cancer Inst.88, 291–296 (1996).
   PubMed Web of Science ®Google Scholar
• Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil. Steril.71, 853–859 (1999).
   PubMed Web of Science ®Google Scholar
• Henderson B, Pike M, Bernstein L, Ross R. Breast Cancer (Second Edition). Oxford University Press, NY, USA (1996).
   Google Scholar
• Kaaks R, Berrino F, Key T et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl Cancer Inst.97, 755–765 (2005).
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Missmer SA, Tworoger SS et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J. Natl Cancer Inst.98, 1406–1415 (2006).
   PubMed Web of Science ®Google Scholar
• Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am. J. Epidemiol.114, 209–217 (1981).
   PubMed Web of Science ®Google Scholar
• Ron E, Lunenfeld B, Menczer J et al. Cancer incidence in a cohort of infertile women. Am. J. Epidemiol.125, 780–790 (1987).
   PubMed Web of Science ®Google Scholar
• Key TJ, Pike MC. The role of estrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol.24, 29–43 (1988).
   PubMedGoogle Scholar
• Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer56, 1206–1208 (1985).
   PubMed Web of Science ®Google Scholar
• Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol. Rev.15, 48–65 (1993).
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Elias SG, Onland-Moret NC et al. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol. Biomarkers Prev.14(4), 799–804 (2005).
   PubMed Web of Science ®Google Scholar
• Masters JR, Drife JO, Scarisbrick JJ. Cyclic variation of DNA synthesis in human breast epithelium. J. Natl Cancer Inst.58, 1263–1265 (1977).
   PubMed Web of Science ®Google Scholar
• Meyer JS. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine: effects of menstrual phase, age, and oral contraceptive hormones. Hum. Pathol.8, 67–81 (1977).
   PubMed Web of Science ®Google Scholar
• Micheli A, Muti P, Secreto G et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int. J. Cancer112, 312–318 (2004).
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil. Steril.69, 963–969 (1998).
   PubMed Web of Science ®Google Scholar
• Kramer EA, Seeger H, Kramer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor – and estradiol-treated human cancerous and benign breast cells. Eur. J. Obstet. Gynecol. Reprod. Biol.129, 77–83 (2006).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med.332(24), 1589–1593 (1995).
   PubMed Web of Science ®Google Scholar
• Baron JA, Weiderpass E, Newcomb PA et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control12, 875–880 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein–Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer79, 494–499 (1997).
   PubMed Web of Science ®Google Scholar
• Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br. J. Cancer75, 1699–1703 (1997).
   PubMed Web of Science ®Google Scholar
• Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am. J. Epidemiol.134, 818–824 (1991).
   PubMed Web of Science ®Google Scholar
• Oktay K, Kim JY, Barad D, Babayev S. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J. Clin. Oncol.28(2), 240–244 (2010).
   PubMed Web of Science ®Google Scholar
• Keefe DL, Franco S, Liu L et al. Telomere length predicts embryo fragmentation after in vitro fertilization in women – toward a telomere theory of reproductive aging in women. Am. J. Obstet. Gynecol.192, 1256–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J. Clin. Endocrinol. Metab.75, 1497–1502 (1992).
   PubMed Web of Science ®Google Scholar
• Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology142, 2351–2360 (2001).
   PubMed Web of Science ®Google Scholar
• Bai W, Oliveros-Saunders B, Wang Q, Cevedo-Duncan ME, Nicosia SV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev. Biol. Anim.36, 657–666 (2000).
   PubMed Web of Science ®Google Scholar
• Ivarsson K, Sundfeldt K, Brannstrom M, Janson PO. Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth inhibitor. Gynecol. Oncol.82, 116–121 (2001).
   PubMed Web of Science ®Google Scholar
• McDonnel AC, Murdoch WJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J. Steroid Biochem. Mol. Biol.78, 185–191 (2001).
   PubMed Web of Science ®Google Scholar
• Pike MC. Age-related factors in cancers of the breast, ovary and endometrium. J. Chronic Dis.40, 59–69 (1987).
   Google Scholar
• Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr. Relat. Cancer7, 73–83 (2000).
   PubMed Web of Science ®Google Scholar
• Goldin BR, Adlercreutz H, Gorbach SL et al. The relationship between estrogen levels and diets of Caucasian–American and Oriental immigrant women. Am. J. Clin. Nut.44, 945–953 (1986).
   PubMed Web of Science ®Google Scholar
• Bernstein L, Yuan JM, Ross RK et al. Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles. Cancer Causes Control1, 51–58 (1990).
   PubMed Web of Science ®Google Scholar
• Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology57(2), 45–48 (1999).
   PubMedGoogle Scholar
• Fathalla MF. Incessant ovulation – a factor in ovarian neoplasia? Lancet2(7716), 163 (1971).
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet343, 692–695 (1994).
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J. Clin.50, 7–33 (2000).
   PubMed Web of Science ®Google Scholar
• Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol.176, 572–579 (1997).
   PubMed Web of Science ®Google Scholar
• Ness RB, Cramer DW, Goodman MT et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case–control studies. Am. J. Epidemiol.155, 217–224 (2003).
   Google Scholar
• Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int. J. Gynecol. Obstet.59, 245–250 (1997).
   PubMedGoogle Scholar
• Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int. Gynecol. Pathol.20, 133–139 (2001).
   PubMed Web of Science ®Google Scholar
• Duczman L, Ballweg ML. Endometriosis and cancer: what is the connection? Endometr. Assoc. Newsl.20 (1999).
   Google Scholar
• Ness RB, Grisso JA, Cottreau C et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology11, 111–117 (2000).
   PubMed Web of Science ®Google Scholar
• Brinton LA, Lamb EJ, Moghissi KS et al. Ovarian cancer risk associated with varying causes of infertility. Fertil. Steril.82(2), 405–414 (2004).
   PubMed Web of Science ®Google Scholar
• Brinton LA, Westhoff CL, Scoccia B et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology16(4), 500–507 (2005).
   PubMed Web of Science ®Google Scholar
• Green A, Purdie D, Bain C et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer survey of women’s health study group. Int. J. Cancer71, 948–951 (1997).
   PubMedGoogle Scholar
• Hankinson SE, Hunter DJ, Colditz GA et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. J. Amer. Med. Ass.270, 2813–2818 (1993).
   PubMed Web of Science ®Google Scholar
• Cattanach J. Oestrogen deficiency after tubal ligation. Lancet1, 847–849 (1985).
   PubMed Web of Science ®Google Scholar
• Rivera R, Gaitan JR, Ruiz R et al. Menstrual patterns and progesterone circulating levels following different procedures of tubal occlusion. Contraception40, 157–169 (1989).
   PubMedGoogle Scholar
• Wu E, Xiao B, Yan W, Li H, Wu B. Hormonal profile of the menstrual cycle in Chinese women after tubal sterilization. Contraception45, 583–593 (1992).
   PubMedGoogle Scholar
• Oliver RTD. Atrophy, hormones, genes and viruses in aetiology of germ cell tumours. Cancer Surveys9, 263–268 (1990).
   PubMedGoogle Scholar
• Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann. Epidemiol.5, 310–314 (1995).
   PubMedGoogle Scholar
• Whittemore AS, Harris R, Itnyre J; the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women. Am. J. Epidemiol.136, 1184–1203 (1992).
   PubMed Web of Science ®Google Scholar
• Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl Cancer Inst.71, 717–721 (1983).
   PubMedGoogle Scholar
• Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br. Med. J.294, 1518–1520 (1987).
   PubMed Web of Science ®Google Scholar
• Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol.30, 230–236 (2005).
   Google Scholar
• Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol.100, 58–64 (2006).
   PubMed Web of Science ®Google Scholar
• Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated Fallopian tube carcinoma: a distinct clinical phenotype? Obstet. Gynecol.106, 1327–1334 (2005).
   PubMed Web of Science ®Google Scholar
• Colgan TJ. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int. J. Gynecol. Pathol.22, 109–120 (2003).
   PubMedGoogle Scholar
• Crum CP, Drapkin R, Miron A et al. The distal Fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin.Obstet. Gynecol.19, 3–9 (2007).
   PubMed Web of Science ®Google Scholar
• Vanderhyden BC. Loss of ovarian function and the risk of ovarian cancer. Cell Tissue Res.322, 117–124 (2005).
   PubMed Web of Science ®Google Scholar
• Murphy ED. Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. J. Natl Cancer Inst.48, 1283–1295 (1972).
   PubMedGoogle Scholar
• Murphy ED, Beamer WG. Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx/Wv genotype. Cancer Res.33, 721–723 (1973).
   PubMedGoogle Scholar
• Scully RE. Pathology of ovarian cancer precursors. J. Cell Biochem. Suppl.23, 208–218 (1995).
   PubMedGoogle Scholar
• Menczer J, Modan M, Ranon L, Golan A. Possible role of mumps virus in the etiology of ovarian cancer. Cancer43, 1375–1379 (1979).
   PubMed Web of Science ®Google Scholar
• Hardiman P, Nieto JJ, MacLean AB. Infertility and ovarian cancer. Gynecol. Oncol.76, 1–2 (1999).
   Web of Science ®Google Scholar
• Yao HH, DiNapoli L, Capel B. Meiotic germ cells antagonize mesonephric cell migration and testis cord formation in mouse gonads. Development130, 5895–5902 (2003).
   PubMedGoogle Scholar
• Mazaud S, Oreal E, Guigon CJ, Carre-Eusebe D, Magre S. Lhx9 expression during gonadal morphogenesis as related to the state of cell differentiation. Gene Expr. Patterns2, 373–377 (2002).
   PubMedGoogle Scholar
• Lee Y, Miron A, Drapkin RA et al. A candidate precursor to serous carcinoma that originates in the distal Fallopian tube. J. Pathol.211(1), 26–35 (2007).
   PubMed Web of Science ®Google Scholar
• CP Crum. The female genital tract. In: Robbins and Cotran’s Pathologic Basis of Disease (7th Edition). Kumar V, Fausto N, Abbas A (Eds). Saunders, PA, USA, 1059–1118 (2004).
   Google Scholar
• Marquez RT, Baggerly KA, Patterson AP et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal Fallopian tube, endometrium, and colon. Clin. Cancer Res.11(17), 6116–6126 (2005).
   PubMedGoogle Scholar
• Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am. J. Epidemiol.171(1), 45–53 (2010).
   PubMed Web of Science ®Google Scholar
• Parazzini F, Chiaffarino F, Negri E et al. Risk factors for different histological types of ovarian cancer. Int. J. Gynecol. Cancer14(3), 431–436 (2004).
   PubMedGoogle Scholar
• Chiaffarino F, Parazzini F, Bosetti C et al. Risk factors for ovarian cancer histotypes. Eur. J. Cancer43(7), 1208–1213 (2007).
   PubMedGoogle Scholar
• Riman T, Dickman PW, Nilsson S et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case–control study. Am. J. Epidemiol.156(4), 363–373 (2002).
   PubMed Web of Science ®Google Scholar
• Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol.31(2), 161–169 (2001).
   Google Scholar
• Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J. Natl Cancer Inst.68(1), 95–98 (1982).
   PubMedGoogle Scholar
• Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br. J. Cancer96(1), 151–156 (2007).
   PubMed Web of Science ®Google Scholar
• Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann. Epidemiol.11(8), 568–574 (2001).
   PubMedGoogle Scholar
• Riman T, Dickman PW, Nilsson S et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl Cancer Inst.94(7), 497–504 (2002).
   PubMed Web of Science ®Google Scholar
• Purdie DM, Webb PM, Siskind V, Bain CJ, Green AC. The different etiologies of mucinous and nonmucinous epithelial ovarian cancers. Gynecol. Oncol.88(1 Pt 2), S145–S148 (2003).
   Google Scholar
• Soegaard M, Jensen A, Høgdall E et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol. Biomarkers Prev.16(6), 1160–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Tung KH, Goodman MT, Wu AH et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case–control study. Am. J. Epidemiol.158(7), 629–638 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2–negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev.36(3), 206–215 (2010).
   PubMedGoogle Scholar